Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET
Company Participants
Lisa Miller - Vice President, Investor Relations
Rick Hawkins - Chief Executive Officer & Chairman
John McKew - President & Chief Scientific Officer
Lori Lawley - Chief Financial Officer
Duke Pitukcheewanont - Chief Medical Officer
Conference Call Participants
Liam Hiester - Piper Sandler
Charles Duncan - Cantor Fitzgerald
Leland Gershell - Oppenheimer & Co.
Ed White - H.C. Wainwright
Catherine Novack - Jones Research
Operator
Greetings, and welcome to Lumos Pharma First Quarter 2024 Financial Results and Clinical Programs Update Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Ms. Lisa Miller, Vice President, Investor Relations. Thank you, Ms. Miller. You may begin. Ms. Miller, go ahead.
Lisa Miller
Before we proceed with the call -- yes, sorry. Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC.
The forward-looking looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise these forward-looking statements.
Information presented on this call is contained in the press release we issued yesterday afternoon and in our Form 8-K, which may be accessed from the Investors page of the Lumos Pharma website.
Speaking on today's call will be Rick Hawkins, CEO and Chairman; John McKew, President and Chief Scientific Officer; and Lori Lawley, Chief Financial Officer. Dr. Duke Pitukcheewanont, Chief Medical Officer, will also join the call for the question-and-answer session.
It's now my pleasure to turn the call over to Rick for our opening remarks.
Rick Hawkins
Thank you, Lisa, and good morning, everyone. I'm pleased to be speaking with you today to provide an update on our progress advancing LUM-201 as the first oral therapeutic for moderate pediatric growth hormone deficiency, or PGHD.
Our recent months have been incredibly productive at Lumos marked by significant milestones. We've had a constructive End-of-Phase 2 Meeting with the FDA and conducted fresh analysis on updated data from our OraGrowtH212 and 210 trials. I'll keep my opening remarks concise before handing over to my colleagues to review in greater detail the strides we've made so far this year. So, let's begin.